Knight Therapeutics (TSE:GUD) Sets New 1-Year High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD)’s stock price hit a new 52-week high on Tuesday. The company traded as high as C$10.41 and last traded at C$10.41, with a volume of 22311 shares traded. The stock had previously closed at C$10.27.

Knight Therapeutics Price Performance

The business has a 50-day simple moving average of C$9.79 and a two-hundred day simple moving average of C$8.81. The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29. The stock has a market capitalization of C$1.02 billion, a price-to-earnings ratio of 69.13, a P/E/G ratio of -1,013.50 and a beta of -0.29.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%.The firm had revenue of C$143.97 million during the quarter. As a group, research analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.